理肺平喘方治疗慢性阻塞性肺疾病稳定期有效性的真实世界队列研究

注册号:

Registration number:

ITMCTR2025000897

最近更新日期:

Date of Last Refreshed on:

2025-05-06

注册时间:

Date of Registration:

2025-05-06

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

理肺平喘方治疗慢性阻塞性肺疾病稳定期有效性的真实世界队列研究

Public title:

A Real-World Cohort Study on the Efficacy of the Lung-Regulating and Asthma-Relieving Prescription in the Treatment of the Stable Phase of Chronic Obstructive Pulmonary Disease

注册题目简写:

English Acronym:

研究课题的正式科学名称:

理肺平喘方治疗慢性阻塞性肺疾病稳定期有效性的真实世界队列研究

Scientific title:

A Real-World Cohort Study on the Efficacy of the Lung-Regulating and Asthma-Relieving Prescription in the Treatment of the Stable Phase of Chronic Obstructive Pulmonary Disease

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘健

研究负责人:

刘健

Applicant:

LIUJIAN

Study leader:

LIUJIAN

申请注册联系人电话:

Applicant telephone:

13616118792

研究负责人电话:

Study leader's telephone:

13616118792

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

ss8738@163.com

研究负责人电子邮件:

Study leader's E-mail:

ss8738@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

江苏省常州市新北区薛家人民医院

研究负责人通讯地址:

江苏省常州市新北区薛家人民医院

Applicant address:

Xuejia People's Hospital Xinbei District Changzhou City Jiangsu Province

Study leader's address:

Xuejia People's Hospital Xinbei District Changzhou City Jiangsu Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

常州市新北区薛家人民医院

Applicant's institution:

Xuejia People's Hospital Xinbei District Changzhou City

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2025001

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

常州市新北区薛家人民医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Xuejia People's Hospital Xinbei District Changzhou City

伦理委员会批准日期:

Date of approved by ethic committee:

2025/3/24 0:00:00

伦理委员会联系人:

周焕刚

Contact Name of the ethic committee:

ZHOUHUANGANG

伦理委员会联系地址:

江苏省常州市新北区薛家人民医院

Contact Address of the ethic committee:

Xuejia People's Hospital Xinbei District Changzhou City Jiangsu Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

13861228398

伦理委员会联系人邮箱:

Contact email of the ethic committee:

xjrmyyllwyh@163.com

研究实施负责(组长)单位:

常州市新北区薛家人民医院

Primary sponsor:

Xuejia People's Hospital Xinbei District Changzhou City

研究实施负责(组长)单位地址:

常州市新北区薛家人民医院

Primary sponsor's address:

Xuejia People's Hospital Xinbei District Changzhou City

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏省

市(区县):

常州市

Country:

China

Province:

jiangsu

City:

changzhou

单位(医院):

常州市新北区薛家人民医院

具体地址:

江苏省常州市新北区薛家人民医院

Institution
hospital:

Xuejia People's Hospital Xinbei District Changzhou City

Address:

Xuejia People's Hospital Xinbei District Changzhou City Jiangsu Province

经费或物资来源:

自筹

Source(s) of funding:

Self-funded

研究疾病:

慢性阻塞性肺疾病

研究疾病代码:

Target disease:

Chronic Obstructive Pulmonary Disease

Target disease code:

研究类型:

Study type:

治疗研究

Treatment study

研究设计:

Study design:

队列研究

Cohort study

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

1.评价理肺平喘方治疗慢性阻塞性肺疾病稳定期的有效性与安全性; 2.为理肺平喘方治疗慢性阻塞性肺疾病稳定期的临床推广提供高质量循证医学依据。

Objectives of Study:

1. To evaluate the effectiveness and safety of the Lung-Regulating and Asthma-Relieving Prescription in the treatment of the stable phase of chronic obstructive pulmonary disease. 2. To provide high-quality evidence-based medical evidence for the clinical promotion of the Lung-Regulating and Asthma-Relieving Prescription in the treatment of the stable phase of chronic obstructive pulmonary disease.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1.符合 COPD 诊断标准的患者; 2.年龄 40 周岁~85 周岁的患者; 3.签署知情同意书且依从性较高的患者。

Inclusion criteria

1. Patients who meet the diagnostic criteria for Chronic Obstructive Pulmonary Disease (COPD). 2. Patients aged between 40 and 85 years old. 3. Patients who have signed the informed consent form and have a high degree of compliance.

排除标准:

1.合并可导致气短或呼吸困难的其他疾病; 2.正在参加其他药物临床试验者; 3.妊娠和准备妊娠的妇女,哺乳期妇女; 4.近期有合并感染性疾病者; 5 合并有心、脑、肝、肾、造血、内分泌系统等严重原发性疾病,肝、肾功能不全(ALT/AST/Cr 大于正常值上限 1.5 倍),精神病患者。

Exclusion criteria:

1. Patients complicated with other diseases that can cause shortness of breath or dyspnea. 2. Patients who are currently participating in other drug clinical trials. 3. Pregnant women and women preparing for pregnancy as well as lactating women. 4. Patients who have had a concurrent infectious disease recently. 5. Patients complicated with severe primary diseases of the heart brain liver kidney hematopoietic endocrine system etc. those with liver and kidney insufficiency (ALT/AST/Cr greater than 1.5 times the upper limit of the normal value) and patients with mental illnesses.

研究实施时间:

Study execute time:

From 2025-04-30

To      2026-05-30

征募观察对象时间:

Recruiting time:

From 2025-05-06

To      2026-05-06

干预措施:

Interventions:

组别:

暴露组

样本量:

100

Group:

Exposure group

Sample size:

干预措施:

理肺平喘方

干预措施代码:

Intervention:

Prescription for Regulating the Lung and Relieving Asthma

Intervention code:

组别:

非暴露组

样本量:

100

Group:

Non-exposure group

Sample size:

干预措施:

西医常规基础治疗

干预措施代码:

Intervention:

Conventional basic treatment of Western medicine

Intervention code:

样本总量 Total sample size : 200

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

江苏省

市(区县):

常州市

Country:

china

Province:

jiangsu

City:

changhzou

单位(医院):

常州市新北区薛家人民医院

单位级别:

二级甲等医院

Institution/hospital:

Xuejia People's Hospital Xinbei District Changzhou City

Level of the institution:

Second-class Grade-A hospital

测量指标:

Outcomes:

指标中文名:

六分钟步行试验

指标类型:

次要指标

Outcome:

Six-Minute Walk Test

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

COPD 急性加重在试验周期内的发生频率

指标类型:

主要指标

Outcome:

The occurrence frequency of acute exacerbation of COPD within the trial cycle

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医症状积分

指标类型:

主要指标

Outcome:

Integral of Traditional Chinese Medicine symptoms

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肺功能指标改善情况

指标类型:

次要指标

Outcome:

The improvement of pulmonary function indicators

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

mMRC 呼吸困难量表

指标类型:

次要指标

Outcome:

Modified Medical Research Council (mMRC) Dyspnea Scale Chronic Obstructive Pulmonary Disease

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

CAT 量表

指标类型:

次要指标

Outcome:

Assessment Test (CAT) Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 40
Min age years
最大 85
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

no

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不公开原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Do not disclose the original data.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

EDC

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统